Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
Ishibashi Y, Muramatsu T, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, Cho YK, Garcia-Garcia HM, van Boven AJ, Piek JJ, Sabaté M, Helqvist S, Baumbach A, McClean D, de Sousa Almeida M, Wasungu L, Miquel-Hebert K, Dudek D, Chevalier B, Onuma Y, Serruys PW. Ishibashi Y, et al. Among authors: suwannasom p. JACC Cardiovasc Interv. 2015 Jul;8(8):1053-1063. doi: 10.1016/j.jcin.2015.06.001. JACC Cardiovasc Interv. 2015. PMID: 26205444 Free article. Clinical Trial.
Comparative analysis method of permanent metallic stents (XIENCE) and bioresorbable poly-L-lactic (PLLA) scaffolds (Absorb) on optical coherence tomography at baseline and follow-up.
Nakatani S, Sotomi Y, Ishibashi Y, Grundeken MJ, Tateishi H, Tenekecioglu E, Zeng Y, Suwannasom P, Regar E, Radu MD, Räber L, Bezerra H, Costa MA, Fitzgerald P, Prati F, Costa RA, Dijkstra J, Kimura T, Kozuma K, Tanabe K, Akasaka T, Di Mario C, Serruys PW, Onuma Y. Nakatani S, et al. Among authors: suwannasom p. EuroIntervention. 2016 Dec 20;12(12):1498-1509. doi: 10.4244/EIJY15M10_03. EuroIntervention. 2016. PMID: 26448577 Free article.
Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II).
Ishibashi Y, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, Garcia-Garcia HM, Bartorelli AL, Whitbourn R, Chevalier B, Abizaid A, Ormiston JA, Rapoza RJ, Veldhof S, Onuma Y, Serruys PW. Ishibashi Y, et al. Among authors: suwannasom p. JACC Cardiovasc Interv. 2015 Nov;8(13):1715-26. doi: 10.1016/j.jcin.2015.07.026. JACC Cardiovasc Interv. 2015. PMID: 26585622 Free article. Clinical Trial.
Bioresorbable drug-eluting scaffolds for treatment of vascular disease.
Suwannasom P, Sotomi Y, Tateishi H, Tenekecioglu E, Zeng Y, Kraak RP, Wykrzykowska JJ, De Winter RJ, Serruys PW, Onuma Y. Suwannasom P, et al. Expert Opin Drug Deliv. 2016;13(5):725-39. doi: 10.1517/17425247.2016.1153062. Epub 2016 Mar 1. Expert Opin Drug Deliv. 2016. PMID: 26865247 Review.
Quantitative assessment of the stent/scaffold strut embedment analysis by optical coherence tomography.
Sotomi Y, Tateishi H, Suwannasom P, Dijkstra J, Eggermont J, Liu S, Tenekecioglu E, Zheng Y, Abdelghani M, Cavalcante R, de Winter RJ, Wykrzykowska JJ, Onuma Y, Serruys PW, Kimura T. Sotomi Y, et al. Among authors: suwannasom p. Int J Cardiovasc Imaging. 2016 Jun;32(6):871-83. doi: 10.1007/s10554-016-0856-6. Epub 2016 Feb 22. Int J Cardiovasc Imaging. 2016. PMID: 26898315 Free PMC article.
Edge Vascular Response After Resorption of the Everolimus-Eluting Bioresorbable Vascular Scaffold　- A 5-Year Serial Optical Coherence Tomography Study.
Tateishi H, Suwannasom P, Sotomi Y, Nakatani S, Ishibashi Y, Tenekecioglu E, Abdelghani M, Cavalcante R, Zeng Y, Grundeken MJ, Albuquerque FN, Veldhof S, Onuma Y, Serruys PW; investigators of the ABSORB Cohort B study. Tateishi H, et al. Among authors: suwannasom p. Circ J. 2016 Apr 25;80(5):1131-41. doi: 10.1253/circj.CJ-15-1325. Epub 2016 Mar 3. Circ J. 2016. PMID: 26936236 Free article. Clinical Trial.
The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
Suwannasom P, Sotomi Y, Ishibashi Y, Cavalcante R, Albuquerque FN, Macaya C, Ormiston JA, Hill J, Lang IM, Egred M, Fajadet J, Lesiak M, Tijssen JG, Wykrzykowska JJ, de Winter RJ, Chevalier B, Serruys PW, Onuma Y. Suwannasom P, et al. JACC Cardiovasc Interv. 2016 Jun 27;9(12):1231-1242. doi: 10.1016/j.jcin.2016.03.027. Epub 2016 Jun 1. JACC Cardiovasc Interv. 2016. PMID: 27262861 Free article.
Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents: Intravascular Ultrasound Assessment From the ABSORB II Trial.
Sotomi Y, Ishibashi Y, Suwannasom P, Nakatani S, Cho YK, Grundeken MJ, Zeng Y, Tateishi H, Smits PC, Barragan P, Kornowski R, Gershlick AH, Windecker S, van Geuns RJ, Bartorelli AL, de Winter RJ, Tijssen J, Serruys PW, Onuma Y. Sotomi Y, et al. Among authors: suwannasom p. JACC Cardiovasc Interv. 2016 Jun 27;9(12):1216-1227. doi: 10.1016/j.jcin.2016.03.022. Epub 2016 Jun 20. JACC Cardiovasc Interv. 2016. PMID: 27339838 Free article. Clinical Trial.
62 results